Cargando…
Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
Most currently recommended therapies for metabolic dysfunction-associated fatty liver disease (MAFLD) involve diet control and exercise therapy. We searched PubMed and compiled the most recent research into possible forms of programmed cell death in MAFLD, including apoptosis, necroptosis, autophagy...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103580/ https://www.ncbi.nlm.nih.gov/pubmed/33962586 http://dx.doi.org/10.1186/s11658-021-00254-z |
_version_ | 1783689334437707776 |
---|---|
author | Zhao, Jianan Hu, Yiyang Peng, Jinghua |
author_facet | Zhao, Jianan Hu, Yiyang Peng, Jinghua |
author_sort | Zhao, Jianan |
collection | PubMed |
description | Most currently recommended therapies for metabolic dysfunction-associated fatty liver disease (MAFLD) involve diet control and exercise therapy. We searched PubMed and compiled the most recent research into possible forms of programmed cell death in MAFLD, including apoptosis, necroptosis, autophagy, pyroptosis and ferroptosis. Here, we summarize the state of knowledge on the signaling mechanisms for each type and, based on their characteristics, discuss how they might be relevant in MAFLD-related pathological mechanisms. Although significant challenges exist in the translation of fundamental science into clinical therapy, this review should provide a theoretical basis for innovative MAFLD clinical treatment plans that target programmed cell death. |
format | Online Article Text |
id | pubmed-8103580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81035802021-05-10 Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy Zhao, Jianan Hu, Yiyang Peng, Jinghua Cell Mol Biol Lett Review Most currently recommended therapies for metabolic dysfunction-associated fatty liver disease (MAFLD) involve diet control and exercise therapy. We searched PubMed and compiled the most recent research into possible forms of programmed cell death in MAFLD, including apoptosis, necroptosis, autophagy, pyroptosis and ferroptosis. Here, we summarize the state of knowledge on the signaling mechanisms for each type and, based on their characteristics, discuss how they might be relevant in MAFLD-related pathological mechanisms. Although significant challenges exist in the translation of fundamental science into clinical therapy, this review should provide a theoretical basis for innovative MAFLD clinical treatment plans that target programmed cell death. BioMed Central 2021-05-07 /pmc/articles/PMC8103580/ /pubmed/33962586 http://dx.doi.org/10.1186/s11658-021-00254-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Zhao, Jianan Hu, Yiyang Peng, Jinghua Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy |
title | Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy |
title_full | Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy |
title_fullStr | Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy |
title_full_unstemmed | Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy |
title_short | Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy |
title_sort | targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (mafld): a promising new therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103580/ https://www.ncbi.nlm.nih.gov/pubmed/33962586 http://dx.doi.org/10.1186/s11658-021-00254-z |
work_keys_str_mv | AT zhaojianan targetingprogrammedcelldeathinmetabolicdysfunctionassociatedfattyliverdiseasemafldapromisingnewtherapy AT huyiyang targetingprogrammedcelldeathinmetabolicdysfunctionassociatedfattyliverdiseasemafldapromisingnewtherapy AT pengjinghua targetingprogrammedcelldeathinmetabolicdysfunctionassociatedfattyliverdiseasemafldapromisingnewtherapy |